AMPH
Amphastar Pharmaceuticals In
NASDAQ · Pharmaceuticals
$29.26
+0.63 (+2.20%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 646.12M | 544.37M | 350.85M | 348.56M | 350.56M |
| Net Income | 140.81M | 106.77M | 71.93M | 62.09M | 65.15M |
| EPS | — | — | — | — | — |
| Profit Margin | 21.8% | 20.7% | 20.5% | 17.8% | 18.6% |
| Rev Growth | +18.7% | +18.7% | +17.0% | -2.5% | +16.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 303.28M | 303.28M | 171.80M | 168.00M | 150.95M |
| Total Equity | 369.00M | 369.00M | 767.61M | 806.96M | 710.94M |
| D/E Ratio | 0.82 | 0.82 | 0.22 | 0.21 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 195.94M | 156.83M | 120.49M | 110.01M | 124.87M |
| Free Cash Flow | — | — | 32.51M | 39.29M | 36.18M |